Single agent lenalidomide induces a response in refractory T-cell posttransplantation lymphoproliferative disorder.
Portell
Craig
C
Nand
Sucha
S
D004351:Drug Resistance / Q000187:drug effects; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000009:adverse effects*; D000077269:Lenalidomide; D008232:Lymphoproliferative Disorders / Q000188:drug therapy* / Q000209:etiology*; D008875:Middle Aged; D013601:T-Lymphocytes / Q000187:drug effects / Q000473:pathology*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
D007155:Immunologic Factors; D013792:Thalidomide; D000077269:Lenalidomide